Parkin Mutations and Their Functional Consequences
Recruitment status was Active, not recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Parkinson's disease (PD) is the most frequent neurodegenerative disease with a prevalence of 2% over 65 years and because of this high prevalence as the population ages, it is a major problem of public health.
An exhaustive repertory of not only parkin mutations in autosomal recessive forms of PD but also in other known genes such as DJ-1, PINK1 and LRRK2, is of major importance for both genetic counseling in families affected with PD and physiopathological approaches to this disease.
Through a French network for the study of Parkinson's disease genetics and extended collaborations with European, Mediterranean and other various countries, a total of 2934 subjects including 1683 patients and 1251 unaffected individuals has been collected since 2002. These samples consisted of 122 families with autosomal recessive PD, 285 cases of isolated early onset PD, 110 autosomal recessive and 129 autosomal dominant families with late onset PD, 201 isolated late onset PD cases and 250 matched controls.
DNAs from all subjects are now available, lymphocytes and lymphoblastoid cell lines have been stored for most patients from France and recently, fresh fibroblasts have been obtained for some individuals.
The genetic approach to autosomal recessive PD is focused on the identification of mutations in the parkin gene but also on the screening of DJ-1, PINK1 and LRRK2 genes.
| Study Type: | Observational |
| Study Design: | Time Perspective: Prospective |
| Official Title: | Parkin Mutations and Their Functional Consequences |
Eligibility| Ages Eligible for Study: | 18 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Patients presenting with Parkinson's disease, with a family history or not,
- Minors presenting clinical signs of the disease,
- Controls (without signs of the disease, matched by sex and age with the patients, relatives for the familial cases)
Exclusion Criteria:
- Persons refusing to sign the informed consent,
- Lack of clinical information
Contacts and Locations| France | |
| Hôpital Pitié-Salpêtrière | |
| Paris, France, 75013 | |
| Principal Investigator: | Alexis Brice, MD | Assistance Publique - Hôpitaux de Paris, University Paris 6 |
More Information
Additional Information:
Publications:
| Responsible Party: | Alexis Brice, Inserm |
| ClinicalTrials.gov Identifier: | NCT00136721 History of Changes |
| Other Study ID Numbers: | 9HD01H, R01NS41723-01A1 |
| Study First Received: | August 26, 2005 |
| Last Updated: | December 3, 2007 |
| Health Authority: | France: Ministry of Health |
Keywords provided by Institut National de la Santé Et de la Recherche Médicale, France:
|
Parkinson's disease phenotype-genotype correlations mutations spectrum candidate genes |
Additional relevant MeSH terms:
|
Parkinson Disease Parkinsonian Disorders Basal Ganglia Diseases Brain Diseases |
Central Nervous System Diseases Nervous System Diseases Movement Disorders Neurodegenerative Diseases |
ClinicalTrials.gov processed this record on May 23, 2013